Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant.

doi:10.1080/00952990.2019.1674864

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant.

The American journal of drug and alcohol abuse - 1 Jan 2020

Shorter Daryl I, Zhang Xuefeng, Domingo Coreen B, Nielsen Ellen M, Kosten Thomas R, Nielsen David A

Abstract excerpt

Background: The α1 antagonist doxazosin reduces cocaine use in individuals with cocaine use disorder (CUD) through a functional polymorphism of the α1 adrenoreceptor. The regulatory role of the α1adrenoreceptor subtype D (ADRA1D) gene polymorphism in CUD is uncharacterized.Objectives: To study how the genetic variant of ADRA1D gene (T1848A, rs2236554) may affect the treatment efficacy of doxazosin in reducing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cocaine-Related Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cognitive Behavioral Therapy

Share to Combined Modality Therapy

Share to Double-Blind Method

Share to Pharmacogenetics

Share to Pilot Projects

Share to Polymorphism, Genetic

Share to Receptors, Adrenergic, alpha-1

Source

Open in PubMed

Identifiers

PMID: 31914324
DOI: 10.1080/00952990.2019.1674864

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant.PMID 31914324Read ↗

Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin.Semantic proximity Read ↗

The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals.Semantic proximity Read ↗

Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.Semantic proximity Read ↗

A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment.Semantic proximity Read ↗

α2A -Adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users.Semantic proximity Read ↗

The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients.Semantic proximity Read ↗

Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations.Semantic proximity Read ↗

Dopamine beta-hydroxylase gene (DbetaH) -1021C-->T influences self-reported paranoia during cocaine self-administration.Semantic proximity Read ↗

ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.Semantic proximity Read ↗

Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.Semantic proximity Read ↗

Genetic and epigenetic analysis of the serotonin 2A receptor in the context of cocaine abuse.Semantic proximity Read ↗

Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.